GPCR Modulation of Thieno[2,3-b]pyridine Anti-Proliferative Agents

Molecules

Euphemia Leung¹  Suat Sari²  Ayesha Zafar³  Jóhannes Reynisson³  Michelle van Rensburg³  Lisa I. Pilkington³  David Barker³ 

[1] Auckland Cancer Society Research Centre and Department of Molecular Medicine and Pathology, University of Auckland, 1142 Auckland, New Zealand;Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey;School of Chemical Sciences, University of Auckland, 23 Symonds Street, 1142 Auckland, New Zealand;

关键词: docking;    molecular and homology modelling;    drug discovery;    chemical space;   

DOI  :  10.3390/molecules22122254

来源: DOAJ

【 摘 要 】

A panel of docking scaffolds was developed for the known molecular targets of the anticancer agents, thieno[2,3-b]pyridines, in order to glean insight into their mechanism of action. The reported targets are the copper-trafficking antioxidant 1 protein, tyrosyl DNA phosphodiesterase 1, the colchicine binding site in tubulin, adenosine A2A receptor, and, finally, phospholipase C-δ1. According to the panel, the A2A receptor showed the strongest binding, inferring it to be the most plausible target, closely followed by tubulin. To investigate whether the thieno[2,3-b]pyridines modulate G protein-coupled receptors (GPCRs) other than A2A, a screen against 168 GPCRs was conducted. According to the results, ligand 1 modulates five receptors in the low µM region, four as an antagonist; CRL-RAMP3 (IC50—11.9 µM), NPSR1B (IC50—1.0 µM), PRLHR (IC50—9.3 µM), and CXCR4 (IC50—6.9 µM). Finally, one agonist, GPRR35, was found (EC50 of 7.5 µM). Molecular modelling showed good binding to all of the receptors investigated; however, none of these surpass the A2A receptor. Furthermore, the newly-identified receptors are relatively modestly expressed in the cancer cell lines most affected by the thieno[2,3-b]pyridines, making them less likely to be the main targets of the mechanism of action for this compound class. Nevertheless, new modulators against GPCRs are of an interest as potential hits for further drug development.

【 授权许可】

Unknown